Mesoblast (MESO) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

MESO Stock Forecast


Mesoblast stock forecast is as follows: an average price target of $11.50 (represents a -32.66% downside from MESO’s last price of $17.08) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

MESO Price Target


The average price target for Mesoblast (MESO) is $11.50 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $11.00. This represents a potential -32.66% downside from MESO's last price of $17.08.

MESO Analyst Ratings


Buy

According to 11 Wall Street analysts, Mesoblast's rating consensus is 'Buy'. The analyst rating breakdown for MESO stock is 0 'Strong Buy' (0.00%), 6 'Buy' (54.55%), 3 'Hold' (27.27%), 2 'Sell' (18.18%), and 0 'Strong Sell' (0.00%).

Mesoblast Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 24, 2024Jason McCarthyMaxim Group$12.00$6.7478.04%-29.73%
Jul 23, 2024Edward TenthoffPiper Sandler$11.00$8.2733.01%-35.58%

The latest Mesoblast stock forecast, released on Sep 24, 2024 by Jason McCarthy from Maxim Group, set a price target of $12.00, which represents a 78.04% increase from the stock price at the time of the forecast ($6.74), and a -29.73% decrease from MESO last price ($17.08).

Mesoblast Price Target by Period


1M3M12M
# Anlaysts-12
Avg Price Target-$12.00$11.50
Last Closing Price$17.08$17.08$17.08
Upside/Downside-100.00%-29.73%-32.66%

In the current month, the average price target of Mesoblast stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Mesoblast's last price of $17.08. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jul 23, 2024Piper SandlerOverweightUpgrade
Aug 31, 2023CitigroupOverweightOverweightHold
Aug 31, 2023Argus ResearchBuyUpgrade
Aug 31, 2023Canaccord GenuityBuyUpgrade
Aug 31, 2023BMO CapitalOutperformUpgrade
Aug 31, 2023CitigroupBuyUpgrade
Aug 31, 2023Wells FargoEqual-WeightUpgrade
Aug 31, 2023JefferiesHoldBuyUpgrade
Aug 31, 2023OppenheimerPerformDowngrade
Aug 31, 2023SusquehannaNegativeDowngrade
Aug 31, 2023CLSAUnderperformDowngrade
Aug 31, 2023Redburn PartnersNeutralUpgrade
Aug 31, 2023Morgan StanleyUnderweightDowngrade
Aug 04, 2023William BlairOutperformMarket PerformDowngrade
Mar 09, 2023William BlairOutperformInitialise
Dec 06, 2022JefferiesHoldDowngrade

Mesoblast's last stock rating was published by Piper Sandler on Jul 23, 2024. The company Upgrade its MESO rating from "null" to "Overweight".

Mesoblast Financial Forecast


Mesoblast Revenue Forecast

Jun 30Mar 30Jun 29Mar 29Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
Revenue---------------------------$1.94M$1.98M$1.44M
Avg Forecast$20.99M$20.99M$4.10M$3.87M$3.87M$2.14M$2.10M$3.47M$7.59M$2.10M$3.50M$2.35M$17.71M$29.20M$15.63M$40.58M$12.71M$9.05M$4.13M$2.09M$2.09M$1.52M$4.08M$3.81M$6.84M$5.60M$2.38M$2.14M$2.10M$3.47M
High Forecast$20.99M$20.99M$4.10M$3.87M$3.87M$2.14M$2.10M$3.47M$7.59M$2.10M$3.50M$2.35M$17.71M$29.20M$15.63M$40.58M$12.71M$9.05M$4.13M$2.09M$2.09M$1.52M$4.09M$3.81M$6.84M$5.60M$2.38M$2.14M$2.10M$3.47M
Low Forecast$20.99M$20.99M$4.10M$3.87M$3.87M$2.14M$2.10M$3.47M$7.59M$2.10M$3.50M$2.35M$17.71M$29.20M$15.63M$40.58M$12.71M$9.05M$4.13M$2.09M$2.09M$1.52M$4.07M$3.81M$6.84M$5.60M$2.38M$2.14M$2.10M$3.47M
# Analysts111111111111111111111211111111
Surprise %---------------------------0.91%0.94%0.42%

Mesoblast's average Quarter revenue forecast for Jun 23 based on 1 analysts is $2.38M, with a low forecast of $2.38M, and a high forecast of $2.38M. MESO's average Quarter revenue forecast represents a 22.92% increase compared to the company's last Quarter revenue of $1.94M (Mar 23).

Mesoblast EBITDA Forecast

Jun 30Mar 30Jun 29Mar 29Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
# Analysts111111111111111111111211111111
EBITDA---------------------------$-13.47M$-20.03M$-14.90M
Avg Forecast$-20.99M$-20.99M$-4.10M$-3.87M$-3.87M$-2.14M$-2.10M$-3.47M$-7.59M$-2.10M$-3.50M$-2.35M$-17.71M$-29.20M$-15.63M$-40.58M$-12.71M$-9.05M$-4.13M$-2.09M$-2.09M$-1.52M$-4.08M$-3.81M$-6.84M$-5.60M$-2.38M$-2.14M$-2.10M$-3.47M
High Forecast$-20.99M$-20.99M$-4.10M$-3.87M$-3.87M$-2.14M$-2.10M$-3.47M$-7.59M$-2.10M$-3.50M$-2.35M$-17.71M$-29.20M$-15.63M$-40.58M$-12.71M$-9.05M$-4.13M$-2.09M$-2.09M$-1.52M$-4.07M$-3.81M$-6.84M$-5.60M$-2.38M$-2.14M$-2.10M$-3.47M
Low Forecast$-20.99M$-20.99M$-4.10M$-3.87M$-3.87M$-2.14M$-2.10M$-3.47M$-7.59M$-2.10M$-3.50M$-2.35M$-17.71M$-29.20M$-15.63M$-40.58M$-12.71M$-9.05M$-4.13M$-2.09M$-2.09M$-1.52M$-4.09M$-3.81M$-6.84M$-5.60M$-2.38M$-2.14M$-2.10M$-3.47M
Surprise %---------------------------6.30%9.54%4.30%

undefined analysts predict MESO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Mesoblast's previous annual EBITDA (undefined) of $NaN.

Mesoblast Net Income Forecast

Jun 30Mar 30Jun 29Mar 29Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
# Analysts111111111111111111111211111111
Net Income---------------------------$-18.60M$-24.49M$-16.88M
Avg Forecast$-194.13M$-191.58M$-300.57M$-363.15M$-363.15M$-268.02M$-226.05M$-263.72M$-165.50M$-217.97M$-328.31M$-310.82M$-157.43M$-64.59M$-204.52M$-56.51M$-284.18M$-293.87M$-297.09M$-407.69M$-407.69M$-419.81M$-317.88M$-309.08M$-300.57M$-209.90M$-235.74M$-268.02M$-226.05M$-263.72M
High Forecast$-194.13M$-191.58M$-300.57M$-363.15M$-363.15M$-268.02M$-226.05M$-263.72M$-165.50M$-217.97M$-328.31M$-310.82M$-157.43M$-64.59M$-204.52M$-56.51M$-284.18M$-293.87M$-297.09M$-407.69M$-407.69M$-419.81M$-317.88M$-309.08M$-300.57M$-209.90M$-235.74M$-268.02M$-226.05M$-263.72M
Low Forecast$-194.13M$-191.58M$-300.57M$-363.15M$-363.15M$-268.02M$-226.05M$-263.72M$-165.50M$-217.97M$-328.31M$-310.82M$-157.43M$-64.59M$-204.52M$-56.51M$-284.18M$-293.87M$-297.09M$-407.69M$-407.69M$-419.81M$-317.88M$-309.08M$-300.57M$-209.90M$-235.74M$-268.02M$-226.05M$-263.72M
Surprise %---------------------------0.07%0.11%0.06%

Mesoblast's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MESO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Mesoblast SG&A Forecast

Jun 30Mar 30Jun 29Mar 29Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
# Analysts111111111111111111111211111111
SG&A---------------------------$12.65M$14.28M$11.76M
Avg Forecast$123.98M$123.98M$24.19M$22.85M$22.85M$12.64M$12.40M$20.48M$44.86M$12.40M$20.67M$13.85M$104.63M$172.48M$92.32M$239.68M$75.05M$53.46M$24.38M$12.35M$12.35M$9.00M$24.09M$22.51M$40.39M$33.08M$14.08M$12.64M$12.40M$18.63M
High Forecast$123.98M$123.98M$24.19M$22.85M$22.85M$12.64M$12.40M$20.48M$44.86M$12.40M$20.67M$13.85M$104.63M$172.48M$92.32M$239.68M$75.05M$53.46M$24.38M$12.35M$12.35M$9.00M$24.14M$22.51M$40.39M$33.08M$14.08M$12.64M$12.40M$18.63M
Low Forecast$123.98M$123.98M$24.19M$22.85M$22.85M$12.64M$12.40M$20.48M$44.86M$12.40M$20.67M$13.85M$104.63M$172.48M$92.32M$239.68M$75.05M$53.46M$24.38M$12.35M$12.35M$9.00M$24.04M$22.51M$40.39M$33.08M$14.08M$12.64M$12.40M$18.63M
Surprise %---------------------------1.00%1.15%0.63%

Mesoblast's average Quarter SG&A projection for Jun 23 is $14.08M, based on 1 Wall Street analysts, with a range of $14.08M to $14.08M. The forecast indicates a 11.27% rise compared to MESO last annual SG&A of $12.65M (Mar 23).

Mesoblast EPS Forecast

Jun 30Mar 30Jun 29Mar 29Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
# Analysts111111111111111111111211111111
EPS---------------------------$-0.13$-0.17$-0.12
Avg Forecast$-0.23$-0.23$-0.35$-0.43$-0.43$-0.31$-0.27$-0.31$-0.19$-0.26$-0.39$-0.37$-0.18$-0.08$-0.24$-0.07$-0.33$-0.35$-0.35$-0.48$-0.48$-0.49$-0.37$-0.36$-0.35$-0.25$-0.28$-0.31$-0.27$-0.31
High Forecast$-0.23$-0.23$-0.35$-0.43$-0.43$-0.31$-0.27$-0.31$-0.19$-0.26$-0.39$-0.37$-0.18$-0.08$-0.24$-0.07$-0.33$-0.35$-0.35$-0.48$-0.48$-0.49$-0.37$-0.36$-0.35$-0.25$-0.28$-0.31$-0.27$-0.31
Low Forecast$-0.23$-0.23$-0.35$-0.43$-0.43$-0.31$-0.27$-0.31$-0.19$-0.26$-0.39$-0.37$-0.18$-0.08$-0.24$-0.07$-0.33$-0.35$-0.35$-0.48$-0.48$-0.49$-0.37$-0.36$-0.35$-0.25$-0.28$-0.31$-0.27$-0.31
Surprise %---------------------------0.41%0.64%0.39%

According to undefined Wall Street analysts, Mesoblast's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MESO previous annual EPS of $NaN (undefined).

Mesoblast Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ADTXAditxt$0.26$160.0061438.46%
VRCAVerrica Pharmaceuticals$0.70$12.001614.29%Buy
INZYInozyme Pharma$2.94$16.00444.22%Buy
XFORX4 Pharmaceuticals$0.74$3.67395.95%Buy
LRMRLarimar Therapeutics$4.32$17.00293.52%Buy
ABOSAcumen Pharmaceuticals$1.96$7.00257.14%Buy
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
FENCFennec Pharmaceuticals$6.07$15.75159.47%Buy
NUVBNuvation Bio$2.81$7.00149.11%Buy
ACHLAchilles Therapeutics$0.97$2.00106.19%Buy
LPCNLipocine$5.21$10.0091.94%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
CNTBConnect Biopharma$1.06$1.5041.51%Buy
HOOKHOOKIPA Pharma$2.13$3.0040.85%Buy
ETONEton Pharmaceuticals$12.64$13.002.85%Buy
MESOMesoblast$12.51$11.50-8.07%Buy

MESO Forecast FAQ


Is Mesoblast a good buy?

Yes, according to 11 Wall Street analysts, Mesoblast (MESO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 54.55% of MESO's total ratings.

What is MESO's price target?

Mesoblast (MESO) average price target is $11.5 with a range of $11 to $12, implying a -32.66% from its last price of $17.08. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Mesoblast stock go up soon?

According to Wall Street analysts' prediction for MESO stock, the company can go down by -32.66% (from the last price of $17.08 to the average price target of $11.5), down by -29.73% based on the highest stock price target, and down by -35.58% based on the lowest stock price target.

Can Mesoblast stock reach $30?

MESO's average twelve months analyst stock price target of $11.5 does not support the claim that Mesoblast can reach $30 in the near future.

What are Mesoblast's analysts' financial forecasts?

Mesoblast's analysts financial forecasts for the fiscal year (Jun 2029) are as follows: average revenue is $13.97M (high $13.97M, low $13.97M), average EBITDA is $-13.974M (high $-13.974M, low $-13.974M), average net income is $-1.295B (high $-1.295B, low $-1.295B), average SG&A $82.54M (high $82.54M, low $82.54M), and average EPS is $-1.521 (high $-1.521, low $-1.521). MESO's analysts financial forecasts for the fiscal year (Jun 2030) are as follows: average revenue is $41.98M (high $41.98M, low $41.98M), average EBITDA is $-41.977M (high $-41.977M, low $-41.977M), average net income is $-386M (high $-386M, low $-386M), average SG&A $247.96M (high $247.96M, low $247.96M), and average EPS is $-0.453 (high $-0.453, low $-0.453).

Did the MESO's actual financial results beat the analysts' financial forecasts?

In terms of the last quarterly report (Mar 2023), Mesoblast's revenue was $1.94M, missing the average analysts' forecast of $2.14M by -9.38%. The company's EBITDA was $-13.473M, beating the average prediction of $-2.14M by 529.70%. Mesoblast's net income was $-18.6M, missing the average estimation of $-268M by -93.06%. The company's SG&A was $12.65M, beating the average forecast of $12.64M by 0.12%. Lastly, the company's EPS was $-0.13, missing the average prediction of $-0.315 by -58.70%